NO20041338D0 - Fremgangsmate ved inhibering av kognitiv svekkelse hos voksne med Downs syndrom. - Google Patents
Fremgangsmate ved inhibering av kognitiv svekkelse hos voksne med Downs syndrom.Info
- Publication number
- NO20041338D0 NO20041338D0 NO20041338A NO20041338A NO20041338D0 NO 20041338 D0 NO20041338 D0 NO 20041338D0 NO 20041338 A NO20041338 A NO 20041338A NO 20041338 A NO20041338 A NO 20041338A NO 20041338 D0 NO20041338 D0 NO 20041338D0
- Authority
- NO
- Norway
- Prior art keywords
- adults
- procedure
- receptor antagonist
- glucocorticoid receptor
- cognitive impairment
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 3
- 201000010374 Down Syndrome Diseases 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 title 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 3
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 3
- 231100000876 cognitive deterioration Toxicity 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Toilet Supplies (AREA)
- Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
- Casting Support Devices, Ladles, And Melt Control Thereby (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31665301P | 2001-08-31 | 2001-08-31 | |
| PCT/US2002/027576 WO2003020216A1 (en) | 2001-08-31 | 2002-08-27 | Methods for inhibiting cognitive deterioration in adults with down's syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20041338D0 true NO20041338D0 (no) | 2004-03-31 |
| NO20041338L NO20041338L (no) | 2004-05-28 |
| NO332723B1 NO332723B1 (no) | 2012-12-27 |
Family
ID=23230024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20041338A NO332723B1 (no) | 2001-08-31 | 2004-03-31 | Anvendelse av glukokortikoidreseptorantagonist for fremstilling av medikamenter til inhibering av kognitiv svekkelse hos voksne med Downs syndrom |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7402578B2 (no) |
| EP (1) | EP1432379B1 (no) |
| JP (2) | JP2005501882A (no) |
| KR (1) | KR20040029116A (no) |
| CN (2) | CN1868480A (no) |
| AT (1) | ATE411013T1 (no) |
| CA (1) | CA2459033C (no) |
| DE (1) | DE60229411D1 (no) |
| ES (1) | ES2314103T3 (no) |
| IL (1) | IL160649A0 (no) |
| MX (1) | MXPA04001893A (no) |
| NO (1) | NO332723B1 (no) |
| NZ (1) | NZ531477A (no) |
| WO (1) | WO2003020216A1 (no) |
| ZA (1) | ZA200401754B (no) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050038580A (ko) * | 2001-10-26 | 2005-04-27 | 악조 노벨 엔.브이. | 주요 우울 장애의 치료에 사용되는(11β,17β)-11-(1,3-벤조디옥솔-5-일)-17-히드록시-17-(1-프로피닐)-에스트라-4,9-디엔-3-온의 용도 |
| HRP20110702T1 (hr) | 2007-02-02 | 2011-10-31 | Pfizer Products Inc. | Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora |
| AU2009267016B2 (en) * | 2008-07-01 | 2014-07-03 | Corcept Therapeutics, Inc. | Use of mifepristone for the treatment of Amyotrophic Lateral Sclerosis |
| EP2576582B1 (en) * | 2010-05-26 | 2019-09-18 | Corcept Therapeutics, Inc. | Treatment of muscular dystrophy |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US9457141B2 (en) | 2013-06-03 | 2016-10-04 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| FI3897589T3 (fi) | 2018-12-19 | 2026-01-13 | Corcept Therapeutics Inc | Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä |
| US11285145B2 (en) | 2020-05-27 | 2022-03-29 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| IL319657A (en) | 2022-10-06 | 2025-05-01 | Corcept Therapeutics Inc | Glucocorticoid receptor modulator formulations |
| WO2024092195A1 (en) | 2022-10-28 | 2024-05-02 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001512422A (ja) * | 1997-02-05 | 2001-08-21 | アレリツクス・フアーム−エコ・エル・ピー | 記憶増強のための薬剤 |
| ATE332696T1 (de) * | 1997-10-06 | 2006-08-15 | Univ Leland Stanford Junior | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen |
| KR20010043630A (ko) * | 1998-05-15 | 2001-05-25 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 치매의 치료를 위한 글루코코티코이드 수용체 길항제 |
| US6620802B1 (en) * | 1999-11-23 | 2003-09-16 | Corcept Therapeutics, Inc. | Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
| US20020065259A1 (en) * | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| AU2002319665B2 (en) * | 2001-07-23 | 2006-09-21 | Corcept Therapeutics, Inc. | Methods for preventing antipsychotic-induced weight gain |
-
2002
- 2002-08-27 IL IL16064902A patent/IL160649A0/xx not_active IP Right Cessation
- 2002-08-27 NZ NZ531477A patent/NZ531477A/en not_active IP Right Cessation
- 2002-08-27 DE DE60229411T patent/DE60229411D1/de not_active Expired - Lifetime
- 2002-08-27 KR KR10-2004-7003036A patent/KR20040029116A/ko not_active Ceased
- 2002-08-27 EP EP02770441A patent/EP1432379B1/en not_active Expired - Lifetime
- 2002-08-27 AT AT02770441T patent/ATE411013T1/de not_active IP Right Cessation
- 2002-08-27 CA CA2459033A patent/CA2459033C/en not_active Expired - Fee Related
- 2002-08-27 ES ES02770441T patent/ES2314103T3/es not_active Expired - Lifetime
- 2002-08-27 CN CNA200510132945XA patent/CN1868480A/zh active Pending
- 2002-08-27 JP JP2003524530A patent/JP2005501882A/ja active Pending
- 2002-08-27 WO PCT/US2002/027576 patent/WO2003020216A1/en not_active Ceased
- 2002-08-27 CN CNA028186087A patent/CN1556708A/zh active Pending
- 2002-08-27 MX MXPA04001893A patent/MXPA04001893A/es active IP Right Grant
- 2002-08-28 US US10/230,575 patent/US7402578B2/en not_active Expired - Lifetime
-
2004
- 2004-03-03 ZA ZA2004/01754A patent/ZA200401754B/en unknown
- 2004-03-31 NO NO20041338A patent/NO332723B1/no not_active IP Right Cessation
-
2008
- 2008-12-08 JP JP2008312752A patent/JP2009102343A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1432379B1 (en) | 2008-10-15 |
| ES2314103T3 (es) | 2009-03-16 |
| EP1432379A4 (en) | 2005-07-13 |
| CA2459033C (en) | 2012-05-22 |
| NO20041338L (no) | 2004-05-28 |
| US7402578B2 (en) | 2008-07-22 |
| ZA200401754B (en) | 2005-05-25 |
| KR20040029116A (ko) | 2004-04-03 |
| ATE411013T1 (de) | 2008-10-15 |
| WO2003020216A1 (en) | 2003-03-13 |
| MXPA04001893A (es) | 2005-03-07 |
| CN1868480A (zh) | 2006-11-29 |
| EP1432379A1 (en) | 2004-06-30 |
| JP2009102343A (ja) | 2009-05-14 |
| DE60229411D1 (de) | 2008-11-27 |
| CN1556708A (zh) | 2004-12-22 |
| JP2005501882A (ja) | 2005-01-20 |
| CA2459033A1 (en) | 2003-03-13 |
| HK1062533A1 (en) | 2004-11-12 |
| IL160649A0 (en) | 2004-07-25 |
| NZ531477A (en) | 2006-10-27 |
| US20030064974A1 (en) | 2003-04-03 |
| NO332723B1 (no) | 2012-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0211365A (pt) | Método e kit para inibir ou reverter o ganho de peso em um paciente sendo tratado com uma medicação antipsicótica | |
| NO20041338L (no) | Fremgangsmate ved inhibering av kognitiv svekkelse hos voksne med Downs syndrom. | |
| CA2328411A1 (en) | Glucocorticoid receptor antagonists for the treatment of dementia | |
| NO20003534D0 (no) | Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene | |
| WO2006055752A3 (en) | INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME | |
| TR200301613T2 (tr) | Sapogenin türevleri, bunların sentezi ve kullanımı, bunların kullanım metotları. | |
| HUP0302476A3 (en) | Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins | |
| CA2302586A1 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
| DK1117403T3 (da) | MGLUR5-antagonister til behandling af smerte og angst | |
| HK1047050A1 (zh) | 治疗轻度智力机能缺陷的方法 | |
| CA2440605A1 (en) | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists | |
| BRPI0414558A (pt) | composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide | |
| IL198759A (en) | Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety | |
| NO20023448L (no) | Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin | |
| DK1267847T3 (da) | 5HT2-antagonist til regulering af IOP og behandling af glaucom | |
| ATE342721T1 (de) | Steroide als neurochemische stimulatoren des nasenraumes zur linderung der prämenstrualen symptome | |
| NO20034916L (no) | Anvendelse av glukokortikoid reseptor-spesifikke antagonister ved behandling av delirium | |
| NO20023841D0 (no) | Anvendelse av glukokortikoidreseptorantagonister for forebygging og behandling av sykdommer av reproduksjonssystemethos menn | |
| AU2002219192A1 (en) | Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect | |
| IL149357A0 (en) | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents | |
| NO20040104L (no) | Farmasøytisk sammensetning for administrasjon ved den nasale ruten av østradiol og noretisteron | |
| EP1726307A3 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |